Will Health Insurance Cover Fertility Preservation Before Cancer Treatment?

When a child is diagnosed with cancer, treatment decisions move quickly. Fertility may feel like a distant concern, but some chemotherapy, radiation and surgical treatments can damage reproductive organs or affect the cells needed to produce eggs or sperm later in life. Once treatment begins, certain preservation options may no longer be available.

Editorial Desk

VHealth Partners

What families should know

Health insurance may cover fertility preservation when chemotherapy, radiation, surgery or another medically necessary treatment could impair a child's future fertility. Coverage depends on the health plan, state law, medical-necessity documentation, provider network and whether the proposed procedure is considered established or investigational. Families should verify coverage in writing before treatment begins.

Health insurance may cover some of these services, but coverage is rarely determined by the cancer diagnosis alone. It can depend on the state, the type of health plan, the proposed procedure, the child's developmental stage, the provider network and how medical necessity is documented.

Families need answers before treatment starts, preferably in writing.

Why this question has gained new attention

In 2026, researchers reported the first successful transplantation of human immature testicular tissue that had been frozen before puberty. The tissue had been preserved for 16 years before transplantation, and parts of the graft later produced mature sperm.

The patient received fertility-damaging chemotherapy for sickle cell disease during childhood. Although the underlying condition was not cancer, the preservation decision is relevant to pediatric oncology because some cancer treatments carry similar risks to future fertility.

The finding is encouraging, but it should be interpreted carefully. The research was published as a preprint and had not yet completed peer review at the time of publication. The reported sperm had not yet been shown to result in a pregnancy or live birth. One successful case does not establish predictable outcomes for other patients. See the 2026 immature testicular-tissue transplantation preprint.

The case demonstrates why preservation decisions can have value many years later. It also shows the uncertainty families must consider when tissue is collected before the clinical method for using it has been fully established.

Medical guidance supports discussing fertility early

The 2025 American Society of Clinical Oncology (ASCO) guideline identifies fertility preservation as an important part of care for children, adolescents and adults whose cancer treatment could affect reproductive function. The guidance supports assessing fertility risk, discussing preservation options and referring patients to reproductive specialists early enough to act before treatment begins. Review the 2025 American Society of Clinical Oncology fertility-preservation guideline.

The American Society for Reproductive Medicine (ASRM) also recommends discussing fertility risks and available options before gonadotoxic treatment. Its 2026 American Society for Reproductive Medicine fertility-preservation guidance makes an important distinction:

→Sperm, mature egg and embryo cryopreservation are established methods for appropriate patients.
→Ovarian tissue cryopreservation is no longer considered experimental and may be considered for prepubertal patients or when treatment cannot be delayed for ovarian stimulation.
→Testicular tissue cryopreservation for prepubertal boys remains investigational and is generally offered through an Institutional Review Board (IRB) approved protocol.

These classifications can directly affect coverage. An insurer may cover an established preservation procedure while excluding an investigational one, even when both arise from the same cancer treatment plan. See also the American Society for Reproductive Medicine guidance on experimental fertility-preservation procedures.

State mandates help, but they do not settle every case

A growing number of states require certain health insurance policies to cover standard fertility-preservation services when medically necessary treatment may cause iatrogenic infertility. Iatrogenic infertility means infertility caused by medical treatment, including chemotherapy, radiation or surgery.

Illinois requires covered individual and group policies to pay medically necessary expenses for standard fertility-preservation services when treatment may directly or indirectly cause infertility. The law ties the definition of standard services to evidence-based professional guidance and prohibits certain forms of discrimination, including restrictions based on age. Read the Illinois fertility-preservation coverage law.

New York requires applicable individual, small-group and large-group policies to cover the collection, freezing, preservation and storage of eggs or sperm when treatment may cause iatrogenic infertility. Cost sharing may still apply, and insurers may review the services for medical necessity. New York also states that its mandate does not apply to self-funded plans governed by the Employee Retirement Income Security Act of 1974 (ERISA). Read the New York fertility-preservation insurance guidance.

A family's residence alone does not establish coverage. The policy must be subject to the relevant state law, and the requested procedure must fall within the law's definition of covered services.

First determine what type of plan covers the child

The insurance card may show the name of a major insurance company, but that company may only be administering the plan for an employer. Self-funded employer plans are generally governed by federal law and may not be subject to state benefit mandates. Review the U.S. Department of Labor guidance on health-plan documents and the Employee Retirement Income Security Act health-plan guidance.

Ask the employer's benefits office or plan administrator:

→Is this plan fully insured or self-funded?
→In which state was the policy issued?
→Is the plan subject to our state's fertility-preservation mandate?
→Does the employer provide a fertility-preservation benefit beyond what the law requires?
→Where can we obtain the complete plan document and Summary Plan Description?

Questions to ask the oncology team

The oncology team's documentation often determines whether the insurer sees preservation as medically necessary. A generic referral for "fertility services" may not give the insurer enough information to distinguish medically necessary preservation from elective fertility treatment.

Oncology team checklist

1Which part of the proposed treatment could impair fertility?
2How high is the estimated risk for this specific treatment regimen?
3Does the risk come from chemotherapy, radiation, surgery, stem-cell transplantation or a combination?
4Must treatment begin immediately, or is there time for a fertility consultation?
5Has an urgent referral been made to a pediatric fertility-preservation or oncofertility program?
6What preservation methods are medically possible given the child's age and pubertal development?
7Which options are established, and which remain investigational?
8Could preservation interfere with or delay cancer treatment?
9Will the oncologist provide a letter of medical necessity identifying the planned treatment, fertility risk, time sensitivity and recommended procedure?
10Who on the cancer-center team will coordinate authorization with the insurer?

Questions to ask the insurer

Call the insurer as soon as the treatment plan is known. Ask for a case manager if the initial representative cannot address oncology-related fertility preservation. Record the representative's name, the date and time, and the call-reference number. Do not assume that coverage of collection includes storage or later use -- these may be treated as separate benefits.

Insurer checklist

1Does the plan cover fertility preservation for treatment-induced infertility?
2What exact plan provision governs this benefit?
3Is the answer different for a minor or prepubertal child?
4Is prior authorization required, and which diagnosis and procedure codes will be reviewed?
5Are consultations, medications, surgery, anesthesia, laboratory processing and cryopreservation covered?
6Is initial storage covered, and for how many months or years?
7Does coverage end if the family changes health plans?
8Are future procedures to use the preserved eggs, sperm, embryos or tissue covered?
9Is the proposed procedure classified as standard, experimental or investigational?
10Is the fertility center and storage laboratory in network?
11Can a network exception be granted if no qualified pediatric program is available?
12What deductible, copayment or coinsurance applies?
13Can the insurer provide its answer and relevant medical policy in writing?
14What is the process for an expedited appeal if authorization is denied?

Questions to ask the preservation program

The fertility-preservation program should be able to separate the medical decision from the financial one and explain where uncertainty remains. For experimental procedures, families should understand whether the research program will cover collection, storage or later use, and what happens when the research period ends.

Preservation program checklist

1What procedure is being recommended, and why is it appropriate for this child?
2Is the procedure established or investigational? If investigational, is it offered through an approved research protocol?
3Which parts of the procedure are billed to insurance, and which are billed by the hospital, physician, anesthesiologist, laboratory and storage facility separately?
4Will the program obtain prior authorization and conduct a benefits investigation before the procedure?
5What is the estimated family responsibility, and what are the initial and annual storage charges?
6Where will the tissue or reproductive material be stored, and who owns or controls it while the child is a minor?
7What changes when the child reaches adulthood, and what consent is required before the material can later be used, transferred, discarded or donated?
8What happens if the facility closes, changes ownership or transfers stored material?
9What outcome data are available, and what remains unknown about whether the preserved material can produce a pregnancy or live birth?

If coverage is denied

A denial does not always close the matter. Read the denial letter closely and identify the stated reason. Common reasons include: the service is excluded under the plan; medical necessity was not established; prior authorization was missing; the provider is out of network; the procedure is considered experimental or investigational; or the insurer did not receive sufficient clinical documentation.

The next step should address the specific reason. Ask the oncologist and preservation specialist to submit supporting records, the treatment protocol, a letter of medical necessity and the professional guidance supporting the proposed service.

If treatment must begin soon, request an expedited internal appeal and confirm the filing deadline. Keep one file containing:

→The full plan document and Summary Plan Description
→The insurer's medical policy
→The oncologist's treatment plan and fertility-risk assessment
→The preservation specialist's recommendation
→Prior-authorization submissions, cost estimates and denial letters
→Appeal submissions, call notes with reference numbers, and written approvals

A preservation decision is also a long-term planning decision

Insurance approval addresses today's procedure. It does not resolve every future question. Parents may need to plan for recurring storage expenses, changes in insurance, consent after the child becomes an adult and the possibility that the preserved material may never be usable.

The 2026 testicular-tissue transplant result shows why a decision made before treatment can still affect someone's life 16 years later. It also supports a careful explanation of the limits. Preservation protects a future possibility. It does not guarantee fertility, pregnancy or a biological child.

The immediate task for families is clear: request the fertility-risk assessment before treatment, identify the exact plan governing coverage, obtain a written benefits determination, and understand every cost and consent obligation that continues after the initial procedure.

Frequently asked questions

Does health insurance cover fertility preservation before chemotherapy?

Health insurance may cover fertility preservation when chemotherapy is expected to impair future fertility. Coverage depends on the state, type of health plan, medical-necessity documentation, provider network and proposed procedure. State mandates generally apply only to specified state-regulated policies. Self-funded employer plans may follow different rules. Families should request a written benefit determination and complete any required prior authorization before treatment.

Does a state fertility-preservation mandate apply to every health plan?

No. State mandates generally apply to health insurance policies regulated by that state. A self-funded employer plan governed by the Employee Retirement Income Security Act of 1974 may be exempt. Medicaid, Children's Health Insurance Program, governmental and church-sponsored plans may follow separate rules. The employer or plan administrator should confirm whether the plan is fully insured or self-funded and identify the law governing the coverage.

Is fertility preservation covered for a prepubertal child?

Coverage depends on the plan and procedure. Ovarian tissue cryopreservation is recognized as an established option for selected prepubertal patients. Testicular tissue cryopreservation for prepubertal boys remains investigational under current professional guidance. An insurer may cover an established procedure while excluding an investigational one. The oncology and preservation teams should document why the proposed option is medically appropriate.

Does insurance cover storage of eggs, sperm, embryos or reproductive tissue?

Some plans and state mandates cover initial storage, but the duration and conditions vary. Collection, freezing, storage and future use may be treated as separate benefits. Families should ask who pays the initial charge, whether annual storage is covered, what happens after a plan change and what charges continue if coverage ends.

What should parents do if fertility preservation is denied?

Parents should obtain the written denial and identify the specific reason. The oncology and fertility-preservation teams can submit the treatment plan, fertility-risk assessment, letter of medical necessity and supporting clinical guidance. If cancer treatment must begin soon, the family should request an expedited appeal and ask whether external review is available. All filing deadlines should be confirmed in writing.

Can fertility preservation delay cancer treatment?

Some preservation procedures require time, while others may be completed without a significant delay. The answer depends on the diagnosis, treatment schedule, child's developmental stage and proposed procedure. The oncology and fertility-preservation specialists should make this decision together. Families should not delay medically necessary cancer treatment without the treating oncologist's approval.

Sources and further reading

Questions about health plan benefit design or compliance?

VHealth helps payers, employers and health plan administrators understand benefit obligations, coverage design and compliance requirements across regulated and self-funded arrangements.

Request a Conversation Compliance Advisory